USPTO Patent Grant: Fetal Analyte Monitoring Device

ChangeBridge: Patent Grants - Diagnosis & Surgery (A61B)

Published March 24th, 2026

Detected March 27th, 2026

Summary

The USPTO has granted patent US12582335B2 for a device designed to monitor fetal analyte concentrations. The device utilizes a biosensor and a protrusion for insertion into fetal tissue to detect analyte levels, with VitalTrace Pty Ltd listed as the assignee.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued patent US12582335B2, titled 'Device, system and method for monitoring an analyte concentration in a foetus.' The patent describes a device comprising a biosensor for electrochemical measurement of fetal analytes, a protrusion for insertion into fetal tissue, and a device body. When the body contacts fetal tissue, the protrusion is inserted, allowing the biosensor's reactive substance to interact with the analyte and generate an electronic signal indicative of its concentration.

This patent grant signifies the approval of a novel medical device technology. While not a regulatory rule imposing obligations on companies, it represents a new intellectual property right in the field of fetal monitoring. Companies involved in developing or manufacturing medical devices for prenatal care, particularly those focused on analyte monitoring, should be aware of this granted patent. The assignee, VitalTrace Pty Ltd, now holds exclusive rights to this specific invention within the United States.

Source document (simplified)

← USPTO Patent Grants

Device, system and method for monitoring an analyte concentration in a foetus

Grant US12582335B2 Kind: B2 Mar 24, 2026

Assignee

VitalTrace Pty Ltd

Inventors

Michael Tom Challenor, Arjun Siddharth Kaushik, Sanandan Sudhir, Akshay Akshay, Sheldon Salvio Napoleon Pinto

Abstract

The present invention relates to a device for monitoring a concentration of an analyte in a foetus. The device comprises a biosensor for electrochemically measuring a concentration of an analyte in the foetus, a protrusion configured to be at least partially inserted into foetal tissue, and a device body supporting the biosensor and the protrusion. The device is configured such that when the device body contacts the surface area of the foetal tissue, the device body can be anchored to the foetal tissue and the protrusion can be inserted into the tissue so that the reactive substance of the biosensor electrochemically reacts with the analyte in the foetal tissue and in response to the electrochemical reaction the electrode of the biosensor detects an electronic signal, a strength of the electronic signal being indicative of the concentration of the analyte.